華潤醫藥(03320.HK)擬收購博雅生物(300294.SZ)控股權獲國資委批覆
格隆匯7月6日丨華潤醫藥(03320.HK)公佈,有關建議收購博雅生物製藥集團股份有限公司的控股權("擬議交易")。華潤醫藥控股已收到國務院國有資產監督管理委員會("國資委")發出日期為2021年7月6日的批覆函件(國資產權[2021]301號),據此,國資委(其中包括)原則上批准擬議交易項下擬向華潤醫藥控股轉讓目標公司69,331,978股非限售流通股股份及表決權委託,以及擬認購目標公司之股份。
截至公吿日期,(i)擬議交易中目標公司股份轉讓需待深圳證券交易所合規性確認後、在中國證券登記結算有限公司深圳分公司申請辦理股份過户登記,表決權委託在該目標公司股份轉讓完成後生效;(ii)而擬議交易中認購目標公司股份尚需深圳證券交易所審批通過並經中國證券監督管理委員會註冊後方可實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.